2. WHO. Cardiovascular diseases. Geneva: World Health Organization, 2021.
3. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009; 54, 1561–1575. https://doi.org/10.1016/j. jacc.
2009.04.098
4. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Hlth Dis. 2011;10 183, https://doi.org/10.1186/1476-511X-10-183. PMID: 22011564; PMCID: PMC3224548
5. Monteleone P, Mascagni G, Giannini A, Genazzani, AR, Simoncini T. Symptoms of menopause — global prevalence, physiology and implications. Nat Rev Endocrinol. 2018; 14, 199. https://doi. org/10.1038/nrendo.2017.180
6. Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int Journal Endocrinol. 2014: 730827.
7. Arderiu G, Lambert C, Ballesta C, Moscatiello F, Vilahur G, Badimon L. Cardiovascular risk factors and differential transcriptomic profile of the subcutaneous and visceral adipose tissue and their resident stem cells. Cells. 2020; 9(10):2235. https://doi.org/10.3390/cells9102235
8. Yang J, Hongxia L, Han L, Zhang L, Zhou Y. Association between visceral adiposity index and hypertension among Chinse adults: a nationwide cross- sectional study in the China Health and Nutrition survey. Blood Pres Moni. 2020; 25(5): 271-277.
9. Hosseinpanah F, Barzin M, Mirbolouk M, Abtahi H, Cheraghi L, Azizi F. Lipid accumulation product and incident cardiovascular events in a normal weight population: tehran Lipid and Glucose Study.Eur J Prev Cardiol. 2016; 23 (2):187–193, https://doi.org/10.1177/2047487314558771. Epub 2014 Nov 7. PMID:25381336.
10. El Shikieri AB, Elmugadam A, Elfadil GA. Visceral adipose index, lipid accumulation product, and selected cardiometabolic risk markers among postmenopausal Sudanese women: A cross-sectional study. Hum Nutri Metab. 2023; 34:200222.
11. Mohammadreza B, Farzad H, Davoud K, Fereidoun Prof, AF. Prognostic significance of the complex “Visceral Adiposity Index” vs. simple anthropometric measures: tehran lipid and glucose study. Cardiovas Diabetol. 2012; 11: 20, https://doi.org/10.1186/1475-2840-11-20.
12. Gulbahar A, Caglar GS, Arslanca T. Evaluation of visceral adiposity index with cardiovascular risk factors, biomarkers in postmenopausal women to predict cardiovascular disease: A 10-year study. Experimental Gerontol. 2022; 170:111986
13. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Hlth Sci.2010; 10(3): 248 – 252
14. Richmond W. Cholesterol enzymatic colorimetric test CHOP-PAP method of estimation of total cholesterol in serum. Clin Chem. 1973; 191: 1350-1356.
15. Trinder P. Triglycerides estimation by GPO – PAP method. Ann Clin Chem. 1969; 6:24 – 27.
16. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyamions. J lipid Res. 1970; 11:583-593.
17. Friedawald WT, Levy RT., Fredickson DS. Estimation of the concentration of LDL- Cholesterol without use of plasma ultracentrifuge. Clin Chem. 1972; 18: 499-
520.
18. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A. Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes care. 2010; 33(4): 920-922
19. Ikewuchi CJ, Ikewuchi CC. Alteration of plasma lipid profile and atherogenic indices of cholesterol loaded rats by Tridax Procumbens Linn: implications for the management of obesity and cardiovascular diseases. Biokemistri. 2009; 21:95-99.
20. Dobiásová M. AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006; 52:64-71
21. Anie LP. Clinical Relevance of Non-HDL Cholesterol in Patients with Diabetes. Clin Diabetes. 2008; 26 (1): 3-6.
22. Tyagi R, Dhall M, Kapoor S. Bio-Social Predictors of Hypertension Among Premenopausal and Postmenopausal Women.Sage Open. 2015; 1– 12. DOI: 10.1177/2158244015574227
23. Ogwumike OO, Adeniyi AF, Dosa BT, Sanya AO, Awolola KO. Physical Activity and Pattern of Blood Pressure in Postmenopausal Women with Hypertension in Nigeria. Ethio J Hlth Sci. 2014; 23(2):153-160
24. Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q, Yang H, Liu J, Wang J, Guo Q, Yu Q, Liang X. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis.Frontiers Pharmacol. 2022; 13: 850815. https://doi.org/10.3389/fphar.2022.850815
25. Thurston, RC, Bhasin S, Chang Y, Barinas-Mitchell E, Matthews K A, Jasuja R,Santoro N. Reproductive Hormones and Subclinical Cardiovascular Disease in Midlife Women. J Clin Endocrinol Metab. 2018; 103, 3070–3077. https://doi:10.1210/jc.2018-00579
26. Berg G1, Mesch V, Boero L, Sayegh F, Prada M, Royer M, Muzzio ML, Schreier L, Siseles N Benencia H. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Hormo Metab Res. 2004; 36(4):215-220.
27. Usoro CAO, Adikwu CC, Usoro IN, Nsonwu AC. Lipid profile of postmenopausal women in Calabar Nigeria. Pak J Nutr. 2006; 5(1): 79-82.
28. Kanwar G, Surekha K, Chawala L, Jain N. A comparative study of serumlipid profile between premenopausal and postmenopausal women in Kota, Rajasthan, India. Int J Res Appl Natul Soc Sci. 2014; 2 (8): 61-66.
29. Otolorin EO, Adeyefa I, Osotimehin BO. Clinical, hormonal and biochemical features of menopausal women in Ibadan Nigeria. Afr J Med Sci. 1989; 18 (4): 251-
255.
30. Igweh JC, Nwagha IU, Okaro JM. The effects of menopause on the serum lipid profile of normal females of south east Nigeria. Nig J Physio Sci. 2005; 20 (1-2):
48-53
31. SwarnaLatha M, Vandana RG. A comparative study of serum lipid profile between Pre- and Post- menopausal women. J Dent Med Sci. 2015; 14(4):51- 53.
32. Adu EM, Ukwamedu HA, Oghagbon ES. Assessment of Cardiovascular Risk indices in Type 2 Diabetes Mellitus. Tropi Med Surg. 2015; 3(2): 184:
https://doi:10.4172/2329-9088.1000184
33. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008; 101: 1003-1008
34. Srisawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanan S, Kroll MH. Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am J Clin Pathol. 2011; 136: 20-29.
35. Hamzeh B, Pasder Y, Mirzaei N, Faramani RS, Najafi F, Shakiba E, Darbandi M. Visceral adiposity index and atherogenic index of plasma as useful predictors of risk of cardiovascular disease: evidence from a cohort study in Iran. Lipids in Hlth Dis. 2021; 20: 82. https://doi.org/10.1186/ s12944-021-01505-w
36. Nansseu JRN, Moor VJA, Nouaga MED, Zing-Awona B, Tchanana G, Arthur Ketcha A. Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women. Lipids in Hlth Di.s 2016; 15:49. https:// doi.org/10.1186/s12944-016-0222-7.
37. Niroumand SH, Khajedaluee M, Khadem- Rezaiyan M, Abrishami M, Juya M, Khodaee GH, Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islamic Repub Iran. 2015; 29:240
38. Bo MS, Cheah WL, Lwin S, Moe New T, Win TT, Aung M. Understanding the relationship between atherogenic index of plasma and cardiovascular disease risk factors among staff of a University in Malaysia. Journal Nutr Metabo. 2018; 2018, 6pages.
39. Lee HJ, Jo HN, Kim YH., Kim SC., Joo
JK., Lee KS. Predictive value of lipid accumulation product, fatty liver index, visceral adiposity index for metabolic syndrome according to menopausal status. Met Synd Related Diso. 2018; 16: 477- 482.
- Abstract viewed - 0 times
- PDF downloaded - 0 times
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
© OF Eholor, ME Adu, 2025
Affiliations
OF Eholor
Department of Biochemistry, Faculty of Science, University of Delta, Agbor.
ME Adu
Department of Biochemistry, Faculty of Science, University of Delta, Agbor.
How to Cite
VISCERAL ADIPOSITY INDEX AND ATHEROGENIC INDEX OF PLASMA: SURROGATE MARKERS OF CARDIOVASCULAR RISK IN POSTMENOPAUSAL WOMEN
Vol 11 No 1 (2025): International Journal of Forensic Medical Investigation
Submitted: Sep 15, 2025
Published: Sep 15, 2025
Abstract
Introduction: Cardiovascular disease has become a major cause of death especially in developing countries. This has raised serious concern especially on the health of postmenopausal women due to hormonal imbalance experienced at this transition. Early detection of cardiovascular disease is a key to its prevention. Therefore, this study aims to assess atherogenic index of plasma (AIP) and visceral adiposity index (VAI) as surrogate markers of cardiovascular risk in postmenopausal women.
Materials and Methods: This cross-sectional study recruited randomly a total of two hundred and seventy-six (276) participants which comprises of fifty four percent (54%) postmenopausal and forty six percent (46%) premenopausal subjects. Anthropometric variables such as blood pressure, body mass index, waist circumference, waist to hip ratio were measured while blood lipids and estradiol were estimated using standard methods. Visceral adiposity index, Atherogenic index of plasma, and other cardiovascular risk indices were calculated using standard formula.
Results: The result of the study revealed significantly higher (p<0.05) VAI, AIP, total cholesterol, triglycerides, very low-density lipoprotein, low density lipoprotein and other cardiovascular risk indices in postmenopausal women than premenopausal women. However, there was significantly lower estradiol in postmenopausal women when compared with premenopausal women but no significant difference observed in high density lipoprotein of postmenopausal and premenopausal women when compared.
Conclusion: It is therefore pertinent to note that postmenopausal women are at a greater risk for cardiovascular diseases and that VAI and AIP can be used as alternative screening tool for the evaluation of cardiovascular risk routinely.